Sephadex induces eosinophil migration to the rat and mouse peritoneal cavity:: involvement of mast cells, LTB4, TNF-α, IL-8 and PAF

被引:15
作者
Oliveira, SHP [1 ]
Costa, CHS [1 ]
Ferreira, SH [1 ]
Cunha, FQ [1 ]
机构
[1] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, BR-14049900 Ribeirao Preto, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
eosinophil migration; mast cells; Sephadex; LTB4; IL-8;
D O I
10.1007/PL00000286
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and design: In this study we investigated the chemotactic mediators involved in the Sephadex-induced eosinophil migration into the peritoneal cavities of rats and mice, and which resident peritoneal cells release these mediators. Materials and methods: Sephadex suspension was injected into the peritoneal cavities of rats or mice which were pretreated. or not, with specific drugs that inhibit synthesis or production of the inflammatory mediators and eosinophil chemotactic activities were observed. To investigate the role of resident peritoneal cells as a source of these chemotactic factors, the macrophage population was enhanced or the mast cell population was depleted. The resident cells were also stimulated, in vitro, with Sephadex and the chemotactic activity of the supernatants was determined. Results: Sephadex induced dose and time dependent eosinophil migration in rats and mouse, which were inhibited by dexamethasone and MK 886. BN 52021 only affected the eosinophil migration into the mouse peritoneal cavity. An increase in the macrophage population did not alter the eosinophil migration induced by Sephadex in rat or mouse. However, mast cell population depletion reduced eosinophil migration in rats, but did not alter the migration in mice. Sephadex-stimulated rat mast cells released an eosinophil chemotactic factor whose release was inhibited by dexamethasone and MK 886. Anti-TNF-alpha and anti-IL-8 Abs inhibited the chemotactic activity of the mast cell supernatant. Conclusion: Sephadex-induced eosinophil migration into the rat peritoneal cavity is dependent on mast cells, which release LTB4, TNF-alpha and CINC-1. Conversely, Sephadex-induced eosinophil migration into the mouse peritoneal cavity is mediated by PAF and LTB4, which are not released from resident macrophages or mast cells.
引用
收藏
页码:144 / 153
页数:10
相关论文
共 51 条
  • [1] AURIAULT C, 1983, J IMMUNOL, V131, P464
  • [2] IDENTIFICATION OF LYMPHOCYTES-T, MACROPHAGES, AND ACTIVATED EOSINOPHILS IN THE BRONCHIAL-MUCOSA IN INTRINSIC ASTHMA - RELATIONSHIP TO SYMPTOMS AND BRONCHIAL RESPONSIVENESS
    BENTLEY, AM
    MENZ, G
    STORZ, C
    ROBINSON, DS
    BRADLEY, B
    JEFFERY, PK
    DURHAM, SR
    KAY, AB
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (02): : 500 - 506
  • [3] BOZZA PT, 1991, BRAZ J MED BIOL RES, V24, P957
  • [4] CHANEZ P, 1990, EUR RESPIR J, V3, P1002
  • [5] CHENSUE SW, 1989, J IMMUNOL, V142, P1281
  • [6] COLLINS PD, 1993, IMMUNOLOGY, V79, P312
  • [7] The role of the eosinophil-selective chemokine, eotaxin, in allergic and non-allergic airways inflammation
    Conroy, DM
    Humbles, AA
    Rankin, SM
    Palframan, RT
    Collins, PD
    Griffiths-Johnson, DA
    Jose, PJ
    Williams, TJ
    [J]. MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1997, 92 : 183 - 191
  • [8] EOSINOPHIL ACCUMULATION IN RATS INJECTED WITH SEPHADEX PARTICLES
    COOK, RM
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1990, 20 (05) : 511 - 517
  • [9] A MECHANISM FOR THE ANTIINFLAMMATORY EFFECTS OF CORTICOSTEROIDS - THE GLUCOCORTICOID RECEPTOR REGULATES LEUKOCYTE ADHESION TO ENDOTHELIAL-CELLS AND EXPRESSION OF ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE-1 AND INTERCELLULAR-ADHESION MOLECULE-1
    CRONSTEIN, BN
    KIMMEL, SC
    LEVIN, RI
    MARTINIUK, F
    WEISSMANN, G
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) : 9991 - 9995
  • [10] THE PIVOTAL ROLE OF TUMOR-NECROSIS-FACTOR-ALPHA IN THE DEVELOPMENT OF INFLAMMATORY HYPERALGESIA
    CUNHA, FQ
    POOLE, S
    LORENZETTI, BB
    FERREIRA, SH
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 (03) : 660 - 664